New drug targets rare nerve tumors in people with specific gene loss

NCT ID NCT07549022

Recruiting now Disease control Sponsor: Ankit Mangla, MD Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Aug 12, 2026 · Updated 3 times

Summary

This study tests an experimental drug called BMS-986504 in people with a rare cancer called malignant peripheral nerve sheath tumor (MPNST) that cannot be removed by surgery. Only people whose tumors are missing a gene called MTAP can join. The drug is taken daily by mouth, and the study will check if it can shrink tumors or slow the cancer. About 17 people will take part.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: BMS-986504 (an experimental drug taken by mouth)
What this could lead to: If it works, this could offer a new treatment option for people with MPNST whose tumors have a specific genetic change (MTAP deletion).
What could go wrong: This is a very early, small trial (17 people) testing an experimental drug. It may not shrink tumors or improve survival, and side effects are unknown.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for MALIGNANT PERIPHERAL NERVE SHEATH TUMORS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

malignant peripheral nerve sheath tumor neurofibrosarcoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

MALIGNANT PERIPHERAL NERVE SHEATH TUMORS MPNST

Contacts and locations

Locations

University Hospitals Seidman Cancer Center, Case Comprehensive Cancer Center
RECRUITING

Cleveland, Ohio, 44106, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.